文献速递肝病消化道出血

辛伐他汀联合标准治疗改善肝硬化静脉曲张出血后患者的长期生存:一项开放标签随机对照试验

Simvastatin Addition to Standard of Care Improves Long-Term Survival in Patients With Cirrhosis After Variceal Bleed: An Open Label Randomized Controlled Trial.
PubMed 文献 · Am J Gastroenterol · 2025-07-31

这项单中心开放标签随机对照试验纳入肝硬化(Child-Pugh 5-12分)静脉曲张出血后第5天患者,比较加用辛伐他汀20mg每日一次(n=130)与不加药(n=138)在标准治疗(卡维地洛+套扎)基础上的疗效。24个月随访显示辛伐他汀组全因死亡24例(18%)vs 标准治疗组44例(31%),HR 0.48(95%CI 0.29-0.81,P=0.006),腹水和自发性细菌性腹膜炎发生率较低,严重不良事件两组相似。

要点

  • 静脉曲张出血后第5天加用辛伐他汀20mg每日一次,24个月全因死亡HR 0.48(95%CI 0.29-0.81,P=0.006)。
  • 辛伐他汀组腹水sHR 0.60(0.39-0.92)、自发性细菌性腹膜炎sHR 0.30(0.11-0.81),均低于标准治疗组。
  • 全因失代偿、再出血、肝性脑病、慢加急性肝衰竭两组无显著差异;严重不良事件发生率相似。

核心结论

  • 辛伐他汀可能(may be associated)与经过选择的肝硬化静脉曲张出血后患者生存改善相关,并减少新发/难治性腹水及其并发症的发生率。

研究设计与样本

  • 单中心、开放标签、优效性设计的随机对照试验,纳入Child-Pugh评分5-12分的肝硬化患者,在静脉曲张出血发作第5天随机分为辛伐他汀20mg每日一次组(n=130)与不加药组(n=138),两组均接受标准治疗(卡维地洛和套扎)。

主要发现

  • 随访期间辛伐他汀组24例(18%)死亡,标准治疗组44例(31%)死亡,辛伐他汀的HR为0.48(95%CI 0.29-0.81,P=0.006),意向治疗和符合方案分析(排除17例停用辛伐他汀者)结果相似。
  • 腹水发生率(sHR 0.60,95%CI 0.39-0.92)和自发性细菌性腹膜炎发生率(sHR 0.30,95%CI 0.11-0.81)在辛伐他汀组较低。
  • 全因失代偿(sHR 0.74,95%CI 0.52-1.05)、再出血(sHR 0.87,95%CI 0.57-1.34)、肝性脑病(sHR 0.71,95%CI 0.42-1.19)和慢加急性肝衰竭(sHR 0.65,95%CI 0.39-1.10)两组相当。
  • 严重不良事件发生率相似:辛伐他汀组43% vs 标准治疗组52%,绝对风险差9.1%(95%CI -2.9%至21.0%)。
  • 在Child-Turcotte-Pugh分级(P=0.105)或病因(P=0.39)之间未显示治疗效果异质性。

临床怎么用

  • 作者认为辛伐他汀可能(may be associated)与经过选择的肝硬化静脉曲张出血后患者生存改善相关,并减少新发/难治性腹水及其并发症的发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is limited evidence about efficacy and safety of simvastatin in decompensated cirrhosis. We assessed whether addition of simvastatin to standard of care improves long-term survival in patients with cirrhosis after variceal bleeding. METHODS: This was a single-center open label randomized controlled trial with superiority design. Patients with cirrhosis (Child-Pugh score 5-12) were randomly assigned to receive either simvastatin (20 mg once-daily) (n = 130) or no drug (n = 138) in addition to standard therapy (carvedilol and band ligation) at day 5 of variceal bleeding episode. Primary outcome was all-cause mortality over 24-month follow-up. Secondary outcomes included individual complications of cirrhosis with death before decompensation as a competing event. RESULTS: Baseline characteristics were similar in both groups with a mean age of 45.0 ± 11.5 years and alcohol (48%) being the predominant etiology. Most patients were of Child-Pugh A (34%) and B (50%) stage. Twenty-four patients (18%) on simvastatin and 44 (31%) on standard therapy died over follow-up (hazard ratio [HR] for simvastatin: 0.48 [95% confidence interval 0.29-0.81]; P = 0.006) with similar results on intention to treat and on per-protocol analysis (excluding 17 patients who stopped simvastatin). Incidence of ascites (subdistributional HR [sHR]) 0.60 (0.39-0.92) and spontaneous bacterial peritonitis (sHR 0.30 [0.11-0.81]) was lower in the simvastatin arm. All cause decompensation (sHR 0.74 [0.52-1.05]), rebleeding (sHR 0.87 [0.57-1.34]), hepatic encephalopathy (sHR 0.71 [0.42-1.19]), and acute-on-chronic liver failure (sHR 0.65 [0.39-1.10]) were comparable in both arms. No heterogeneity of treatment effect was demonstrated across Child-Turcotte-Pugh class ( P = 0.105) or etiology ( P = 0.39). Incidence of serious adverse events was similar (43% in simvastatin and 52% in standard therapy, absolute risk difference: 9.1% [-2.9% to 21.0%]). DISCUSSION: Simvastatin may be associated with improved survival in selected patients with cirrhosis after variceal bleed and reduced incidence of new onset/refractory ascites and its complications (CTRI/2022/07/044263).

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Rana R, Tabish M, Agarwal S, et al. Simvastatin Addition to Standard of Care Improves Long-Term Survival in Patients With Cirrhosis After Variceal Bleed: An Open Label Randomized Controlled Trial. Am J Gastroenterol. 2025. PMID: 40736696. doi:10.14309/ajg.0000000000003689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。